Ones To Watch News
Refine Search
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Biotechnology
US artificial intelligence (AI) to gene therapy focussed biotech Dyno Therapeutics has signed a collaboration and license agreement with Roche. 14 October 2020
Biotechnology
California, USA-based biotech A2 Biotherapeutics has closed its $71.5 million Series B financing. 7 October 2020
Pharmaceutical
Shares of Acacia Pharma closed up 4.5% at 2.22 euros today, as the UK company revealed that the US Drug Enforcement Administration (DEA) has designated its procedural sedative Byfavo (remimazolam injection) as a Schedule IV medicine. 6 October 2020
Pharmaceutical
German drugmaker Stada Arzneimittel has strengthened its footprint in specialty pharmaceuticals by acquiring privately-held Swedish drugmaker Lobsor Pharmaceuticals and its innovative therapy used for treating late-stage Parkinson’s disease. 2 October 2020
Biotechnology
Solid Biosciences said yesterday that the US Food and Drug Administration has lifted the clinical hold placed on the company’s IGNITE DMD Phase I/II clinical trial. of SGT-001, a gene transfer candidate under investigation for Duchenne muscular dystrophy (DMD). 2 October 2020
Biotechnology
Dr Daniel Vasella, former chairman and chief executive of Swiss pharma giant Novartis, has been appointed the new and independent chairman of the board of Swiss biotech Numab Therapeutics. 30 September 2020
Biotechnology
The US Food and Drug Administration says it has additional questions about the planned Phase II/III trial of its COVID-19 vaccine candidate INO-4800, including its CELLECTRA 2000 delivery device to be used in the trial. 28 September 2020
Biotechnology
Chinese company Innovent Biologics today announced the results of a Phase III, open label, randomized study in China. 28 September 2020
Biotechnology
California, USA-based Nutcracker Therapeutics, a company developing and producing mRNA therapeutics, today announced not only a financing deal but also a new senior executive. 23 September 2020
Biotechnology
Moderna has announced a collaboration with Italian family-controlled Chiesi Farmaceutici aimed at the discovery and development of mRNA therapeutics for the treatment of pulmonary arterial hypertension (PAH), a rare disease with an incidence of 2-5 per million adults. 17 September 2020
Biotechnology
Influenza prevention specialist Seqirus, part of Australia’s CSL Limited, today announced the publication of real-world evidence (RWE) on the company's cell-based quadrivalent influenza vaccine (QIVc) in peer-reviewed medical journal Vaccine. 16 September 2020
Biotechnology
San Diego, USA-based Escient Pharmaceuticals, which is developing Mas-related G Protein-Coupled Receptor (MRGPR)-targeted drugs to address serious, underserved medical needs across a broad range of therapeutic indications, today announced the completion of a $77.5 million Series B financing. 15 September 2020
Biotechnology
The US Food and Drug Administration has granted Rare Pediatric Disease designation to Ad-RTS-hIL-12 with veledimex (Controlled IL-12) for the investigational treatment of diffuse intrinsic pontine glioma (DIPG), a lethal brain tumor occurring in the pontine region of the brain. 14 September 2020
Biotechnology
Valneva has announced a partnership with USA-based Dynavax Technologies for the supply of Dynavax' CpG 1018 adjuvant for use in Valneva's SARS-CoV-2 vaccine candidate, VLA2001 14 September 2020
Biotechnology
A new precision medicine company, IcanoMAB, has been founded in Polling, Germany. 7 September 2020
Biotechnology
The US Food and Drug Administration (FDA) has approved Gavreto (pralsetinib) for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. 7 September 2020
Biotechnology
Shares of Fortress Biotech, formerly Coronado Biosciences, were up more than 6% at $3.51 in early trading today, after it announced that its Cyprium Therapeutics subsidiary reported positive top-line clinical efficacy results for CUTX-101, a potential treatment for Menkes disease. 28 August 2020
Pharmaceutical
The first novel medicine for acne in decades has been approved in the USA, lifting shares in Italian developer Cassiopea 16% on Thursday, and a further 6% on Friday morning. 28 August 2020
Biotechnology
The impressive effectiveness of Carragelose (carrageenan), a sulfated polymer from red seaweed, against the new SARS-CoV-2 virus is confirmed by more and more studies, says Vienna, Austria-based Marinomed Biotech. 27 August 2020
Biotechnology
Proteostasis Therapeutics has entered into a definitive merger agreement with US neuroscience-focused start-up Yumanity Therapeutics. 24 August 2020
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze